Albireo Pharma (ALBO) Stock Highlights

44.15 | -0.23%

2023-04-04 00:04:18

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Companys product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, its a lead preclinical candidate for the treatment of adult viral and liver diseases.

Statistics

Range Today

43.99 44.9

Volume Today 1.26M

Range 1 Year

16.02 45.23

Volume 1 Year 93.51M

Range 3 Year

11.26 49

Volume 3 Year 197.75M

Range 10 Year

6.6 182.4

Volume 10 Year 258.18M

Highlights

Market Capitalization 915.89M (small)

Floating Shares 14.22M

Current Price 44.15

Price To Earnings -6.74

Price To Revenue 12.22

Price To Book 9.13

Earnings Per Share -6.66

Payout Ratio 0%

Performance

Latest -0.23%

1 Month 0%

3 Months +85.04%

6 Months +157.43%

1 Year +64.43%

3 Years +79.54%

5 Years +25.18%

10 Years -47.63%

Benchmarks

Market Capitalization

131 / 368

Gross Profits

69 / 278

Total Revenue

113 / 300

Total Rank

82 / 368

Free Cashflow

255 / 352

Performance 5 years

91 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.